ADC Therapeutics (ADCT) Stock Price, Quote, News & History | Benzinga

ADC Therapeutics SA (ADCT) Stock Price, Quote, News & History

ADCTNYSE

Trade with Public

Trade with Public

$1.05

Last update: Aug 14, 9:20 AM

PRO

Why Is It Moving?™:ADC Therapeutics shares are trading lower after the company reported mixed ...

Earnings: Q2 2026 Earnings were released on Thu Aug 13th, before the market open

Conference Call: The most recent conference call started at 8:30 AM, 1 day ago

Click to view the webcast

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

-

Volume / Avg.

6.95K / 1.76M

Day Range

- - -

52 Wk Range

0.78 - 4.98

Market Cap

$133.55M

P/E Ratio

-

Dividend Yield

-

Exchange

NYSE

RSI

36

Short Interest

4.72%

Days to Cover

6.11

Recent ADC Therapeutics SA News

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.

Piero Cingari

This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday

Top Wall Street analysts changed outlook on top names. ADCT downgraded See analysts' views.

Avi Kapoor

ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursday's Pre-Market Session (CORRECTED)

U.S. stock futures down on tech profit-taking and weak guidance, ADC Therapeutics shares plunge 50.67%, other stocks also slide.

Avi Kapoor

Why Is ADC Therapeutics Stock Falling On Friday?

Discover why ADC Therapeutics (NYSE:ADCT) stock is tumbling on Friday as a prominent Wall Street analyst slashes targets due to serious trial safety signals.

Kaustubh Bagalkote

Why Is ADC Therapeutics Stock Falling Thursday?

ADC Therapeutics stock plunges premarket as LOTIS-3 trial shows elevated serious, Grade 5 adverse events despite meeting its primary endpoint.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-114.55M

Investing Cash Flow (TTM)

627.00K

Financing Cash Flow (TTM)

150.09M

Free Cash Flow (TTM)

-114.58M

Capital Expenditure (TTM)

-32.00K

Net Change in Cash (TTM)

36.17M

Analyst Trends and Forecast

1

Mar

2

May

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.3

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$32.01M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

1.97

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-55.24%

Earnings Yield % (FWD)

-79.52%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$1.79

Company Debt

Total Debt

$115.68M

LT Debt

$111.04M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$231.01M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

-

Volume / Avg.

6.95K / 1.76M

Day Range

- - -

52 Wk Range

0.78 - 4.98

Market Cap

$133.55M

P/E Ratio

-

Dividend Yield

-

Exchange

NYSE

RSI

36

Short Interest

4.72%

Days to Cover

6.11

About

Sector

Health Care

Industry

Biotechnology

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and ma...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy ADC Therapeutics (ADCT) stock?

A

You can purchase shares of ADC Therapeutics (NYSE:ADCT) through any online brokerage.

View our list of the best stock brokerages

Q

Who are ADC Therapeutics (ADCT) competitors?

A

Other companies in ADC Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for ADC Therapeutics (ADCT) stock?

A

ADC Therapeutics has a consensus price target of $7.00.

Q

What is the current price for ADC Therapeutics (ADCT)?

A

The stock price for ADC Therapeutics (NYSE: ADCT) is $1.05 last updated August 14, 2026 at 9:20 AM EDT.

Q

Does ADC Therapeutics (ADCT) pay a dividend?

A

There are no upcoming dividends for ADC Therapeutics.

Q

When is ADC Therapeutics (NYSE:ADCT) reporting earnings?

A

ADC Therapeutics does not have any upcoming earnings scheduled.

Q

Is ADC Therapeutics (ADCT) going to split?

A

There is no upcoming split for ADC Therapeutics.

Q

What sector and industry does ADC Therapeutics (ADCT) operate in?

A

ADC Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.